Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Cash & Equivalents: 2011-2024

Historic Cash & Equivalents for Adma Biologics (ADMA) over the last 11 years, with Dec 2024 value amounting to $103.1 million.

  • Adma Biologics' Cash & Equivalents fell 29.20% to $61.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $61.4 million, marking a year-over-year decrease of 29.20%. This contributed to the annual value of $103.1 million for FY2024, which is 100.86% up from last year.
  • Per Adma Biologics' latest filing, its Cash & Equivalents stood at $103.1 million for FY2024, which was up 100.86% from $51.4 million recorded in FY2023.
  • In the past 5 years, Adma Biologics' Cash & Equivalents ranged from a high of $103.1 million in FY2024 and a low of $51.1 million during FY2021.
  • For the 3-year period, Adma Biologics' Cash & Equivalents averaged around $80.3 million, with its median value being $86.5 million (2022).
  • In the last 5 years, Adma Biologics' Cash & Equivalents tumbled by 40.65% in 2023 and then skyrocketed by 100.86% in 2024.
  • Adma Biologics' Cash & Equivalents (Yearly) stood at $55.9 million in 2020, then dropped by 8.64% to $51.1 million in 2021, then skyrocketed by 69.36% to $86.5 million in 2022, then crashed by 40.65% to $51.4 million in 2023, then spiked by 100.86% to $103.1 million in 2024.